Illumina, Inc. has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator.
Follow Israel Hayom on Facebook and Twitter
One of the seven is NewStem Ltd., a Jerusalem-based cancer therapeutics and diagnostics company that is developing genetic-based products utilizing a proprietary haploid human embryonic stem cells library of mutations.
The company's website explains that these cells play a "pivotal" role regenerative medicine, disease treatment, and cancer research.
"The global reach of Illumina Accelerator is demonstrated by our investment in these seven diverse startups from six countries," said Amanda Cashin, PhD, co-founder and Global Head of Illumina For Startups. "This diversity is testament to the strength and breadth of the talented entrepreneurs around the world focused on unlocking the power of the genome to improve human health and beyond."
